Cargando…
Values and other decisional factors regarding treatment of hypercalcaemia of malignancy: a systematic review protocol
INTRODUCTION: Hypercalcaemia of malignancy (HCM) is the second most common cause of hypercalcaemia and is associated with significant morbidity and mortality. Several treatment options are available including pharmacological therapy with bisphosphonates, denosumab, glucocorticoids and calcimimetics,...
Autores principales: | Bassatne, Aya, Rahme, Maya, Piggott, Thomas, Murad, M. Hassan, Hneiny, Layal, El-Hajj Fuleihan, Ghada |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506874/ https://www.ncbi.nlm.nih.gov/pubmed/34635523 http://dx.doi.org/10.1136/bmjopen-2021-051141 |
Ejemplares similares
-
The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis
por: Bassatne, Aya, et al.
Publicado: (2021) -
Hypovitaminosis D in the Middle East and North Africa: Prevalence, risk factors and impact on outcomes
por: Bassil, Darina, et al.
Publicado: (2013) -
Vitamin D in the Middle East and North Africa
por: Chakhtoura, Marlene, et al.
Publicado: (2018) -
Treatment of malignant hypercalcaemia with clodronate.
por: Percival, R. C., et al.
Publicado: (1985) -
Qualitative study exploring the perspectives of emerging adults with type 1 diabetes after transfer to adult care from a paediatric diabetes centre in Montreal, Canada
por: Vaillancourt, Monica, et al.
Publicado: (2023)